Ocular fundus manifestation of two patients following long-term chloroquine therapy: a case report
© Ma et al; licensee BioMed Central Ltd. 2010
Received: 16 January 2010
Accepted: 29 March 2010
Published: 29 March 2010
This report describes the typical manifestations of chloroquine retinopathy with some advanced new technology. A series of examinations were performed on the patients, including the fundus fluorescein angiography, optical coherence tomography, GDxVCC Nerve Fiber Analyzer, full-field electroretinography, multifocal electroretinography and visual field examinations, to provide a better understanding of chloroquine retinopathy.
Chloroquine has long been used in the treatment and prevention of malaria[1–4], and for a long time, the agent is still being used to treat other diseases. For example, due to its immunosuppressive effects, chloroquine has been used in the treatment of autoimmune disorders, such as rheumatoid arthritis and lupus erythematosus. Chloroquine has also been tested in clinical trials as an antiretroviral agent against HIV  and as a radiosensitizer and chemosensitizer for human cancer therapy . However, the side effects of Chloroquine, including ocular toxicities, limit its long-term use [2–4, 6].
Herein we describe two patients who developed severe ocular toxicity following long-term chloroquine treatment. The clinical characteristics of their retinopathy were extensively investigated using various techniques, and are reported in this manuscript. We are not trying to provide information which would help in the early screening for chloroquine retinopathy, but to describe the typical manifestations of chloroquine retinopathy with some advanced new technology which have not been applied on this disease before, believing that it would provide a better understanding of chloroquine retinopathy.
A 55-year-old woman had taken chloroquine for rheumatoid arthritis for more than 4 years, with an estimated total dose of 365 g (250 mg daily). She first presented with a history of gradually decreasing visual acuity without any other symptoms approximately two years earlier. The latest examination revealed that her visual acuity was 30/200 OD and 60/200 OS, Goldmann applanation intraocular pressure was normal (OD13 mmHg, OS12 mmHg), the center visual field was severely damaged, and the Goldmann visual field showed central scotoma in both eyes. Her ocular fundus photograph also showed pigmentary deposits and atrophy, attenuation of the retinal artery, waxy pallor of the optic disc, and retinal atrophy (Figure 1 Part C). Differing from Patient 1, FFA of Patient 2 showed marked hyperfluorescence in the macular area with clear demarcations (Figure 1 Part D). Round-shaped blocked fluorescence was seen in the central fovea. OCT showed retinal nerve fiber layer atrophy and irregular RPE signals (Figure 2 Part C and D), however, the central fovea thickness was not decreased to as great an extent as that observed in Patient 1. The RNFL thickness around the optic nerve measured by OCT was normal, which was also supported by the GDxVCC results (Figure 3 Part C and D). The FERG amplitudes were decreased in both eyes, and the mfERG (with 61 stimuli) indicated reduced focal responses with a decrease in amplitude and prolonged peak latency of N1 and P1 responses in both eyes, especially in the ring 1 and 2 (Figure 4 Part C and D). The data of amplitude and peak latency of N1 and P1 response from ring 1 to 5 were shown in Figure 4 Part C and D.
Chloroquine toxicity is not uncommon, especially in patients receiving long-term therapy [1–3]. While hydroxychloroquine is now frequently prescribed instead of chloroquine because of its higher therapeutic window, its use has also been shown to cause retinal damage . Histological analysis of human and animal retinas with chloroquine toxicity has demonstrated the loss of ganglion cells, photoreceptors, and RPE, which likely result from inhibition of lysosomal phospholipases and protein synthesis. However, the initial retinal damage is thought to occur in ganglion cells .
In contrast to the usual clinical observations, there was no major pigment atrophy ring with a clarified boundary around the central fovea (making the characteristic bulls-eye) in the FFA image from our patients. However, we did observe a marked hyperfluorescence in the macular area, possibly due to RPE atrophy. Although it is frequently used in the clinic, full-field ERG may not be a reliable method for identifying early chloroquine retinopathy . In our cases, because the two patients had severe retinopathy, the FERG amplitudes were non-recordable. Therefore, F-ERG analysis may have limited value in the diagnosis of early chloroquine retinopathy, because the toxicity is localized and a full field analysis may not be sensitive to localized retinal toxocity in early disease.
It has been suggested that mfERG is a more sensitive method that can be used to detect chloroquine retinopathy . For example, in one study, even though clinical examinations found no abnormalities in a patient with a long history of hydroxychloroquine use , mfERG showed an absence of foveal rings and the presence of pericentral isoelectric waveforms. In our current report, the patients had severely damaged visual acuity and center visual field loss, mfERG showed a reduction in focal responses and a delay in the peak latency.
There have been some reports in which OCT was used in the detection of chloroquine and hydroxychloroquine-induced retinopathy . In our cases, not only the "bulls-eye" was shown in the fundus photograph, but also the proliferation-atrophy-proliferation changes of the RPE in the macular area were detected by OCT. Confirming these results, the RNFL thickness measured by GDx (GDx Nerve Fiber Analyzer (NFA) is a relatively new and improved technology that uses scanning laser polarimetry (SLP)) was within the normal range in our patients, this result was different from the conclusions of some other reports. For example, Bonanomi et al  reported that mean RNFL thickness measured by GDxFCC from patients using chloroquine were significantly different from the control group in all regions around the optic disc. Possible explanation for this difference might be that the damage of retina in some patients taking chloroquine distributed mainly in the macula area, while the RNFL thickness around the optic disc remained normal.
To the best of our knowledge, this is the first report describing the findings of FFA, OCT, GDxVCC NFA, FERG, mfERG and visual field examinations in the same patients with chloroquine retinopathy. While the fundus pictures from the two patients are similar, there are differences in their macular thickness. Thus, given the differences found using the various methods and instruments, and the well-documented weaknesses of the various techniques, it is evident that multiple analyses are helpful for better understanding of chloroquine retinopathy.
Written informed consent was obtained for publication of these two case reports and accompanying images. Copies of the written consent are available for review by the Editor-in-Chief of this journal.
- Uhlemann AC, Krishna S: Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr Top Microbiol Immunol. 2005, 295: 39-53. full_text.PubMedGoogle Scholar
- Hoobs H, Sorsby A, Freedman A: Retinopathy following chloroquine therapy. Lancet. 1959, 2: 478-480. 10.1016/S0140-6736(59)90604-X.View ArticleGoogle Scholar
- Gilbert ME, Savino PJ: Missing the bull's eye. Surv Ophthalmol. 2007, 52: 440-442. 10.1016/j.survophthal.2007.04.001.View ArticlePubMedGoogle Scholar
- Lyons JS, Severns ML: Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007, 143: 801-809. 10.1016/j.ajo.2006.12.042.View ArticlePubMedGoogle Scholar
- Savarino A, Boelaert JR, Cassone A: Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis. 2003, 3: 722-727. 10.1016/S1473-3099(03)00806-5.View ArticlePubMedGoogle Scholar
- Savarino A, Lucia MB, Giordano F: Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol. 2006, 7: 792-793. 10.1016/S1470-2045(06)70875-0.View ArticlePubMedGoogle Scholar
- Rosenthal AR, Kolb H, Bergsma D: Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci. 1978, 17: 1158-1175.PubMedGoogle Scholar
- Marmor MF, Zrenner E: Standard for clinical electroretinography (1999 update). International society for clinical electrophysiology of vision. Doc Ophthalmol. 1998, 97: 143-156. 10.1023/A:1002016531591.View ArticlePubMedGoogle Scholar
- Nebbioso M, Grenga R, Karavitis P: Early Detection of Macular Changes with Multifocal ERG in Patients on Antimalarial Drug Therapy. Journal of ocular pharmacology and therapeutics. 2009, 25: 1-10. 10.1089/jop.2008.0106.View ArticleGoogle Scholar
- Rodriguez-Padilla JA, Hedges TR, Monson B: High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007, 125: 775-780. 10.1001/archopht.125.6.775.PubMed CentralView ArticlePubMedGoogle Scholar
- Bonanomi MTBC, Dantas NC, Medeiros FA: Retinal nerve fibre layer thickness measurements in patients using chloroquine. Clinical and Experimental Ophthalmology. 2006, 34: 130-136. 10.1111/j.1442-9071.2006.01167.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.